Among U.S. healthcare providers who treat pulmonary arterial hypertension (PAH), a patient’s current treatment, PAH cause, and coexisting health issues are the factors that most influence their willingness to prescribe first-line combination therapy over monotherapy, according to a new study. Most clinicians said they felt a single tablet combination…
Treatment with inhaled nitric oxide (iNO) and pulmonary surfactant within the first three days of life significantly reduces the risk of developing bronchopulmonary dysplasia (BPD) associated with pulmonary hypertension (PH) in preterm infants, according to a recent study in China. “Early intervention using iNO and PS appears to be…
Most people with pulmonary arterial hypertension (PAH) are not referred for a lung transplant, despite clinical recommendations that referral should occur early in potentially eligible cases, a study reports. About 18% to 29% of participants with advanced functional class 4 disease, who guidelines recommend referrals for, received referrals.
Boosting the levels of irisin, a protein found at lower levels in people with pulmonary arterial hypertension (PAH), may help slow disease progression by stopping abnormal cell growth and blood vessel remodeling in the lungs, a study has found. “[I]risin is a novel protective factor against PAH development and is…
Elevated blood levels of a protein called CTRP7 — which are significantly higher in people with pulmonary arterial hypertension (PAH) than in those without the disease — may predict a poor response to Uptravi (selexipag), according to findings from a new study in Japan involving both mice and…
Balloon pulmonary angioplasty (BPA) led to significant clinical improvements for people with chronic thromboembolic pulmonary hypertension (CTEPH) when used as an initial therapy or after a pulmonary endarterectomy (PEA) surgery, according to a global observational study. “Our data are in line with previous reports on changes of clinical and…
The rates of long-term survival and perioperative complications after a lung transplant in people with group 2 or group 3 pulmonary hypertension (PH) aren’t significantly different from those in people who don’t have PH, a study reports. “No significant differences [between group 2 PH, group 3 PH, or no…
Researchers used small particles called extracellular vesicles to deliver a form of apelin directly to damaged blood vessels in the lungs, which helped reverse the damage and improve heart function in animal models of pulmonary arterial hypertension (PAH), according to a study. Apelin, a peptide that plays a role…
Providing a protein called BMPER that is found at low levels in models of pulmonary arterial hypertension (PAH) may ease disease progression, a study suggests. “Our study identifies BMPER as a novel therapeutic target for pulmonary arterial hypertension and provides new insights into the underlying mechanisms of the disease,” researchers wrote.
People with pulmonary arterial hypertension (PAH) with at least one coexisting condition associated with cardiovascular disease had similar rates of hospitalization and mortality as those without these conditions after a combination treatment of macitentan and tadalafil, according to a real-world analysis. There was, however, a tendency towards more adverse…
Following the first commercial sale of Yutrepia (treprostinil) inhalation powder to treat certain types of pulmonary hypertension, the therapy’s maker, Liquidia, has received an additional $50 million under its financing agreement with Healthcare Royalty (HCRx). Per that HCR Agreement, Liquidia has been raising funds by selling HCRx…
A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with pulmonary arterial hypertension (PAH) has completed enrollment. The ADVANCE OUTCOMES trial (NCT03626688) enrolled 728 people with PAH who were on oral background therapies. Participants are being randomly assigned to receive ralinepag at doses…
Get regular updates to your inbox.
